Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Gamma Delta (γδ) T Cells for the Treatment of Glioblastoma

NCT07144735 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07144735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07144735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Gamma Delta (γδ) T Cells for the Treatment of Glioblastoma
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
April 1, 2025
Completion date
December 31, 2030
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm), glioblastoma multiforme (gbm)